On the company"s webpage, PHI"s CEO and founder Peter Egelberg comments the recently published innovation report from the UN agency World Intellectual Property Organization. The report sets PHI"s technology area, single-cell analysis, as the cutting-edge technology that is most likely to revolutionize healthcare over the next decade - outranking high-profile innovations such as regenerative medicine, immunotherapy and gene therapy, see phiab.com/commentary/the-single-cell-analysis-revolution.

For additional information, please contact:
Carolina Silvandersson
E-mail: ir@phiab.se
Web: www.phiab.com – Live cell imaging & analysis

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.